The cumulative incidence of VTE among patients with ALK-negative NSCLC (95% CI) at index and 6-, 12-, 24-, and 60 months post-index were 2.1% (1.7%-2.5%), 7.7% (7.1%-8.4%), 9.9% (9.1%-10.9%), 12.4% (11.5%-13.3%), and 15.1% (14.2%-16.1%) (Fig. 1). Here, ALK is linked to non-small cell lung carcinoma.